about
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEx-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapyHuman gammadelta T cells: a nonredundant system in the immune-surveillance against cancer.HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironmentConstitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target.Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease.BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.A relapsing inflammatory syndrome and active human herpesvirus 8 infection.Double-edged effect of Vgamma9/Vdelta2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection.Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis.LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytes.Bortezomib induces autophagic death in proliferating human endothelial cells.Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.Purification of a glycosaminoglycan-stimulatory lymphokine from supernatants of in vitro-activated human mononuclear cells.Heterogeneous synthetic phenotype of cloned scleroderma fibroblasts may be due to aberrant regulation in the synthesis of connective tissues.MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab.3D-Dynamic Culture Models of Multiple Myeloma.Tocilizumab in patients with multisystem Erdheim-Chester disease.Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.Adenosine induced production of a soluble factor affecting lymphocyte activation.Tumor Necrosis Factor α As a Master Regulator of Inflammation in Erdheim-Chester Disease: Rationale for the Treatment of Patients With InfliximabVariations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas functionInherited Perforin andFasMutations in a Patient with Autoimmune Lymphoproliferative Syndrome and LymphomaCD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and inγ δ T lymphocytesConstitutive expression of the heat shock protein 72 kDa in human melanoma cellsA matter of life and death: More members of the TNF receptor family join human γδ T lymphocytesErdheim-Chester disease: report on a case and new insights on its immunopathogenesisHypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomibImmunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: Implications for pathogenesisMacrophages exposed to Mycobacterium tuberculosis release chemokines able to recruit selected leucocyte subpopulations: focus on gammadelta cellsAutocrine Nitric Oxide Modulates CD95-induced Apoptosis in γδ T LymphocytesDistinct pattern of HSP72 and monomeric laminin receptor expression in human lung cancers infiltrated by γ/δ T lymphocytesVdelta1+ Gamma/Delta T Lymphocytes Infiltrating Human Lung Cancer Express the CD8alpha/alpha HomodimerErdheim-Chester disease: An in vivo human model of Mϕ activation at the crossroad between chronic inflammation and cancer
P50
Q28240576-6844E6E5-851E-4ED6-A396-E86C414010B3Q28535634-F8B0F805-F43E-4F68-B04A-7713A23DF94BQ34500914-31521598-6E82-474F-AE6B-5B870A04C9B8Q37097867-9F757D08-C1C5-4904-843F-FB1A79226050Q37351173-0F2338EF-20C2-40D4-8563-820A96C1FCEEQ39397373-9189454F-6CB7-4171-83F4-71720572A023Q40180256-55968639-4BEA-42CF-91D6-862733211107Q40503902-3C15B7B7-B30F-4610-B7A0-85D9F414E20EQ40669468-104FA95F-8D43-4FB1-80E7-0F33425A72CCQ41758452-66FECFBA-C508-4635-8CD8-FF30A15FD0B6Q42383966-61A1D9D6-7AC8-4178-B2D5-9C8C1CD088F7Q43241228-015B6889-6E9B-45CF-AF79-5EBF24A32B98Q43806000-6769FF86-362B-462F-970D-A61D15CB5A45Q44109592-46B363B0-8AF7-4351-BF5E-59F3663DC2BDQ46236094-1E9BF00A-D21E-4174-B034-2558AEFA3ACFQ46652662-D6642B84-9486-4E46-A0C6-532C06EE8315Q47916252-FA59E376-76D3-4F58-B914-99687E16A42FQ47999671-47F92798-C06B-492F-96BE-EC6E5C165E40Q52763513-15DE70A7-B204-4EEA-AFC5-A4B284DDAB6AQ52885099-1E319EBA-32D7-4382-AA85-AFEF427114A0Q54420949-C222F9D1-0C1F-497A-8C9F-99FFA6D299BFQ57950937-6CBD5297-7F9B-4B90-9155-D03D3C7D86D6Q58049149-C99CB30F-7E0D-45A8-A088-B0B0895AA720Q58049165-F7DFFEB9-0664-4673-8FE9-53642EA85FE3Q58291561-92C32ABD-0C6F-409C-B8C6-A9C63884D305Q58880799-11BEE048-5766-422B-B8FF-7F3D9F67B4F9Q60464831-CDC8D5D9-F4E2-4CBD-920C-4FA98BB2CEC7Q60464834-F9A27CD8-AA2B-4C81-A8BB-B1C018A43CD3Q60464840-62819FA9-108B-4195-88F6-AE1C35549177Q60464842-3BFFAC40-AF62-4837-9693-24E1A38D81F3Q60464850-EEBFA0D6-BE9A-4FA0-9CEB-118A2E7E6D13Q60464854-53036F04-EA03-4D65-BEDF-3511A392DDBCQ60464856-D298D1F4-09AE-4FE1-8BA3-9BAE35CA3A89Q60464857-40FB9806-169C-4657-8B42-25B4392BF214Q89707238-F44B9DA6-7B7F-4806-8C00-C23AF60893AF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marina Ferrarini
@ast
Marina Ferrarini
@en
Marina Ferrarini
@es
Marina Ferrarini
@nl
Marina Ferrarini
@sl
type
label
Marina Ferrarini
@ast
Marina Ferrarini
@en
Marina Ferrarini
@es
Marina Ferrarini
@nl
Marina Ferrarini
@sl
prefLabel
Marina Ferrarini
@ast
Marina Ferrarini
@en
Marina Ferrarini
@es
Marina Ferrarini
@nl
Marina Ferrarini
@sl
P106
P1153
7004413311
P21
P31
P496
0000-0003-1015-9632